Assessment of the Efficacy of Quercetin in Adult Patients With Autism Spectrum Disorder: A Randomized, Triple-Blind, Placebo-Controlled Trial.

Denna randomiserade, trippelblinda och placebokontrollerade studie tilldelade 52 vuxna med autismspektrumtillstånd quercetin eller placebo i 60 dagar. Poängen på Social Responsiveness Scale, WHO:s livskvalitetsdomäner och andra kliniska mått bedömdes vid studiens start samt efter 30 och 60 dagar. Baseline demographics and comorbid conditions were similar between groups.

Within the quercetin group, Social Responsiveness Scale scores declined significantly over time, p = 0.010. The placebo group did not show a significant within-group change, p = 0.655. That contrast is not the decisive test, however: the difference between groups in score change was not statistically significant. At week 8, the physical-health WHO Quality of Life domain favoured quercetin before adjustment, p = 0.044, but was no longer significant after adjustment, p = 0.082. The environmental-health domain was borderline after adjustment, p = 0.053.

The abstract's language about possible benefits is weaker than a confirmed placebokontrollerad effect. This was a short clinical trial in adults with autism spectrum disorder, not a study of healthy ageing or longevity. Its primär between-group social-responsiveness result was null, and the adjusted quality-of-life analyses did not reach conventional statistical significance.

Quercetin showed potential benefits in selected social quality-of-life and responsiveness measures in adults with autism spectrum disorder, pending larger trials.